Pharmacokinetics of IMM-H012 in rats using ultra-performance liquid chromatography-tandem mass spectrometry.
Biomed Chromatogr
; 38(8): e5905, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38806776
ABSTRACT
The present study examined the pharmacokinetics of IMM-H012 in rat plasma, utilizing ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Internal standard cilostazol was employed, and plasma samples were processed using acetonitrile precipitation. A mobile phase (acetonitrile-0.1% formic acid in water) with gradient elution was used to achieve chromatographic separation using a UPLC BEH C18 column. In multiple reaction monitoring mode, electrospray ionization MS/MS was utilized in positive ionization mode. Based on findings, the lower limit of quantification was 2 ng/mL, and the linearity of IMM-H012 in rat plasma was found to be acceptable within the range of 2-2000 ng/mL (R2 > 0.995). The intra-day and inter-day precision relative standard deviation was less than 14% of IMM-H012 in rat plasma. The matrix effect was within the range of 102%-107%, and the accuracy ranged from 92% to 113%. Pharmacokinetics of IMM-H012 in rats after oral administration were successfully studied using UPLC-MS/MS.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rats, Sprague-Dawley
/
Tandem Mass Spectrometry
Limits:
Animals
Language:
En
Journal:
Biomed Chromatogr
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
United kingdom